Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasmapheresis

Severe Sepsis Clinical Trial

Official title: Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasma Therapeutic Exchange

Status Recruiting

Clinical Trial Summary

Sepsis is one of the most prevalent and fatal diseases in intensive care units .unfortunately, therapeutic approach to sepsis has remained unchanged for many years. Nowadays, the role of cytokines in pathogenesis of sepsis is obvious. Continuous elevated levels of various cytokines in severe sepsis could result in uncontrolled inflammation status. Breaking of inflammatory cascade may lead to improvement in survival. It seems that modulation of inflammation is one of the strategic plans to conquest sepsis. Therefore, elimination of bacterial toxins and pro-inflammatory cytokines from the systemic circulation by plasmapheresis supposed to be rational approach.

Researchers have done several attempts to clarify the efficacy of plasmapheresis in sepsis treatment. However because of inconsistent results, routine use of this procedure in patients with severe sepsis remains controversial.

The aim of the present survey is to determine the effect of plasmapheresis on plasma levels of main pro-inflammatory cytokines and evaluate its therapeutic efficacy in improvement of outcome and treatment of severe sepsis.

Clinical Trial Description

Method 27 patients with sepsis less than 24 hours, admitted in ICU, 16- 60 years old, male and female, randomized divided two groups(P=12, S=15) study in randomized clinical trial.

Inclusion criteria:

A: At least 3 of SIRS criteria;

1. 36> Tem> 38 ◦c

2. HR>90 bpm (without medication)

3. RR>20 bpm or PaCo2≤ 32 on mechanical ventilation

4. WBC<4000 or >12000 or > 10% immature neutrophil

B: Documented diagnosis of sepsis (separation organism from blood, urine, CSF, secretions such as trachea and sore) or strong suspect for infection with at least one of following:

1. WBC in sterile area,

2. Perforated viscera,

3. Radiological evidences of pneumonia,

4. High risk of infection such as cholangitis. Severity of disease is appointed with APACHE II (on result of laboratories in last 24 hours)

Exclusion criteria:

1. Pass more than 24 hours from diagnosis of sepsis.

2. High likelihood of mortality (renal failure, hepatic encephalopathy, ….) or imminent death(APACHE II score >25)

3. Pregnant or lactescent woman

4. 16 > age years old

5. No satisfaction of patient

Treatments of S group include:

1. Early goal - directed resuscitation

2. Appropriate diagnostic studies prior to antibiotics

3. Early broad - spectrum antibiotics

4. Narrowing antibiotic therapy based on microbial therapy and clinical data

5. Source control

6. Stress dose steroids for septic shock

7. Target Hb values of 7-9 g/dl in absence of coronary artery disease or acute hemorrhage

8. Lung protective ventilation for ALI/ARDS

9. Avoidance of Neuromuscular blockade

10. Maintenance of blood glucose < 150mg/dl

11. DVT/stress ulcer prophylaxis

In plasmapheresis (P) group, plasmapheresis will add into conventional therapy which is mentioned above. volume of plasmapheresis is 20-40 ml/Kg with five time in a week (distance 24-48 hours) that will do with speed of 60-120 ml/min through of central venous catheter.

Steps of plasmapheresis:

1. calculation of plasma volume

2. PT, PTT, Plt before and after plasmapheresis

3. Replacement plasma with albumin 20% and/or normal saline

4. Check of serum calcium before and after plasmapheresis. Injection of calcium gluconate 10%.

5. Stop of all of drugs (except vasopressor)

6. Cardiovascular monitoring during plasmapheresis

7. Infusion of heparin 500 u/h Demographic characters of patients (age, sex, weight, BMI) will record. Central venous, arterial line and Foley catheter will insert. For all of patients will do follow assays daily: CVP, BP, ABG, BUN, Cr, Na, K, CBC, PLT, PT, PTT, U/A, P, Ca, Mg, Chest X Ray. LFT and Alb

Level of biomarkers evaluate at 1st, 3rd, 5th, 7th and 14th day of study. In P group, evaluation will do before and after of plasmapheresis. Biomarkers include:

1. TNF-α (early release cytokine)(plasma)

2. IL-1 (early release cytokine)(plasma)

3. IL-6 (pro & anti-inflammatory cytokine)(plasma) Patient will evaluate for 14 days or until death. Patient's morbidity will record until 30 days.

Evaluation of morbidity will do by scoring systems:

• TISS score (Therapeutic intervention scoring system): for evaluation of severity of care.

• SOFA score (Sepsis- related organ function assessment): for evaluation of organ function.

• ADL score (Activities of daily living) Recorded information will analyze by t- test for quantitative variables and χ 2 square for qualitative variables, with α = 0/05. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Critical Illness
• Severe Sepsis

• NCT number: NCT01249222
• Study type: Interventional
• Source: Tehran University of Medical Sciences
• Contact: mojtaba mojtahedzadeh, Ph.D
• Phone: 009821-6695-9090
• Email: Mojtahed@sina.tums.ac.ir
• Status: Recruiting
• Phase: N/A
• Start date: November 2008
• Completion date: February 2011